CV Therapeutics^® is a biopharmaceutical company primarily focused on the discovery, development and commercialization of new small molecule drugs for the treatment of cardiovascular diseases. We apply advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery.

	More News
+ CV Therapeutics Reports 2008 Third Quarter Financial Results + FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c + CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008

	Learn More
CV Therapeutics is looking for talented professionals to work in a rapidly growing, results-oriented, progressive research and development environment...